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Abstract
Breast cancer risk has both heritable and environment/lifestyle components. The heritable
component is a small contribution (5–27 %), leaving the majority of risk to environment (e.g.,
applied chemicals, food residues, occupational hazards, pharmaceuticals, stress) and lifestyle (e.g.,
physical activity, cosmetics, water source, alcohol, smoking). However, these factors are not well-
defined, primarily due to the enormous number of factors to be considered. In both humans and
rodent models, environmental factors that act as endocrine disrupting compounds (EDCs) have
been shown to disrupt normal mammary development and lead to adverse lifelong consequences,
especially when exposures occur during early life. EDCs can act directly or indirectly on
mammary tissue to increase sensitivity to chemical carcinogens or enhance development of
hyperplasia, beaded ducts, or tumors. Protective effects have also been reported. The mechanisms
for these changes are not well understood. Environmental agents may also act as carcinogens in
adult rodent models, directly causing or promoting tumor development, typically in more than one
organ. Many of the environmental agents that act as EDCs and are known to affect the breast are
discussed. Understanding the mechanism(s) of action for these compounds will be critical to
prevent their effects on the breast in the future.
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Introduction
Breast cancer is the second most common type of cancer among women in the United States
(second to skin cancers) and the second leading cause of death due to cancer, after lung
cancer [1]. In fact, the most recent US statistics estimate that 1 in 8 women will be
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diagnosed with breast cancer in their lifetime [2], a number that has not declined even
following a dramatic decrease in the use of postmenopausal hormone treatments shown to be
associated with increased breast cancer risk [2]. Breast cancer also affects men, but to a
much lesser degree, with only 1 % of the US male population annually diagnosed [3]. As
with other cancers the formation of breast tumors has a heritable link; between 5 to 27 % of
all breast cancers are attributed to factors such as specific gene mutations, certain traits (i.e.,
dense breasts, fibrocystic disease), and metabolic issues [4]. The environmental and lifestyle
factors that contribute the other 70–95 % of breast cancer risk are largely unknown. Some
general risk factors for breast cancer include: sex, age, parity, age at menarche, and age at
menopause. The importance of environmental influences and exogenous exposures on some
of these factors (parity, age at menarche) have been demonstrated [5, 6], but we have only
begun to understand how exogenous chemicals that disrupt the function of the endocrine
system may increase susceptibility to breast cancer and other diseases.
The endocrine system is composed of multiple glandular organs that secrete hormones
directly into the bloodstream. Organs of the endocrine system have important functions such
as developing and maintaining normal tissue functions, bone health, metabolism,
reproduction, lactation, and stress response, among others. For the purposes of this review,
we will focus primarily on the effects of the endocrine system on reproduction and
metabolism. Hormones secreted from the endocrine system affect nearly every organ and
system within the body. Endocrine disrupting chemicals (EDCs or endocrine disruptors), as
their name suggests, are chemicals that alter normal actions of the endocrine system. EDCs
are defined by the US Environmental Protection Agency as “exogenous agents that interfere
with the production, release, transport, metabolism, binding, action, or elimination of the
natural hormones in the body responsible for the maintenance of homeostasis and the
regulation of developmental processes” [7]. Table 1 lists ways in which chemicals can
disrupt the endocrine system.
Normal growth of the mammary gland involves endocrine signaling from the hypothalamic-
pituitary-gonadal axis. However, autocrine and paracrine hormones and growth factors also
play critical roles in development and regulation of the mammary gland. Some of the many
endocrine hormones and growth factors known to modulate mammary gland development
include: growth hormone, prolactin, oxytocin, epidermal growth factor, insulin, insulin-like
growth factors, adrenal corticosteroids, transforming growth factors, thyroxine, estrogen,
progesterone, activin, and inhibin [8]. Figure 1 illustrates the endocrine-mediated influences
on mammary gland growth and function. This figure becomes complicated by the numerous
possible endocrine-mediated mechanisms/pathways that may be altered by the >84,000
chemicals on the Toxic Substance Control Act Chemical Inventory list [9]. The effects that a
small portion of these chemicals have on mammary gland development are known, but the
link between early life health effects and later life disease, such as the inability to lactate or
breast cancer susceptibility, are less clear.
Chemical Carcinogenesis and Endocrine Disruptors
Although there is a lack of consensus regarding theories of carcinogenesis, tumor maturation
of aberrant cells is thought by some to be regulated by three main events: initiation,
promotion, and progression [10]. Carcinogens, or chemicals that cause tumor growth, can
affect any one or more of these events and may involve dynamics of the genome related to
increased expression of oncogenes, decreased expression of tumor suppressors, disruption of
signal transduction, or changes in expression of cell cycle or apoptosis regulator genes.
Initiation of tumors may result from chemical-induced DNA damage or inherited mutations
of the DNA. Un-checked cellular DNA-damage becomes replicated and leads to mutations
within the genome. Formation of radicals from oxidative damage can also lead to DNA-
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damage. Other heritable, genomic origins of tumors may arise from epigenetic changes.
Epigenetic changes do not involve direct changes of the genome, rather it affects how the
genome is transcribed or translated. This can involve DNA methylation, histone
modification, or RNA mediated modifications. Promotion of tumorigenesis is often
described as reversible alteration in gene expression and tumor progression as irreversible
alteration in gene expression. Tumor growth is promoted through clonal expansion of
mutated cells, concomitant with an increased cellular proliferation rate and decreased
apoptotic rate. There is also merit in the idea that cancer originates from aberrant tissue
organization and not simply aberrant cellular growth [11]. This theory specifically refers to
carcinogenesis as a problem similar to abnormal development—which could explain how
fetal exposure to a non-mutagenic compound predisposes the mammary gland to
carcinogenesis, supporting the theory of fetal origins of adult disease. Under this theory the
unfavorable alterations are reversible under certain conditions.
Some chemicals have been tested for their carcinogenic potential. This is primarily done by
chemical manufacturers and government-funded research, such as the 2 year cancer
bioassays conducted in rodents by the National Toxicology Program (NTP)—chemicals are
nominated by the public, other agencies, or in house for testing [12]- or through other test
guidelines, such as those developed and used within the Organisation for Economic Co-
operation and Development (http://www.oecd.org/env/chemicalsafetyandbiosafety/
testingofchemicals/oecdguidelinesforthetestingofchemicals.htm) and the European Union’s
2007 (Registration, Evaluation, Authorisation and Restriction of Chemical Substances)
REACH regulation. The NTP produces the Report on Carcinogens (RoC) that documents
chemical data which support cancer causation in animals or humans. Approximately 2,500
chemicals have been evaluated and chronic rodent cancer studies (adult only exposure to test
compound for 2 year) have been conducted on just over 600 chemicals. About 250 of those
have shown carcinogenic potential in female rodents, and about 60 of those have shown
evidence as mammary gland carcinogens. However, many of those mammary gland
carcinogens caused cancer in other sites, also. In 2010, the NTP re-instituted experiments
designed to expose the fetus and developing offspring, in addition to the adult, to the test
compounds of interest. There are six substances in the RoC that cause or may cause breast
cancer in humans. These include the drug diethylstilbestrol (DES), steroid hormones used
for menopausal therapy, some forms of radiation, alcohol, tobacco smoke (see Reynolds et
al., this issue), and the sterilizing agent, ethylene oxide.
Although DES is a classical carcinogen [13, 14], it is also an EDC. It is a synthetic estrogen
that interferes in estrogen receptor-mediated signaling to disrupt endocrine-mediated
pathways [14] and is covered in detail elsewhere (see Hilakivi-Clarke et. al, this issue).
There are few examples of EDCs that act as chemical carcinogens; however EDCs have the
potential to influence tumorigenesis by altering lifetime susceptibility to a second ‘hit’ or
exposure [15]. In recent years, examples of altered mammary histoarchitecture [16] and
spontaneous (no second ‘hit’) ductal carcinoma in situ in mice and rats following prenatal
Bisphenol A exposure has been demonstrated (reviewed in [17]). Importantly, these
discoveries suggest that a second hit may or may not be needed for some EDCs to influence
carcinogenesis. In women, it is estimated that 40 % of all cancers are hormonally regulated
[8] and thus there are many potential modes or mechanisms by which EDC exposure could
modify cancer risk. Many factors that influence breast cancer are endocrine-regulated
processes (e.g., age at menarche, age at 1st pregnancy, and age at menopause) and may be
modified by EDCs. EDCs that do not affect DNA are proposed to influence tumorigenesis in
a variety of ways, including impaired or altered 1) epithelial growth rate, 2) stromal
composition of the gland, 3) immune response, 4) response to endogenous hormones, 5)
terminal end bud presence, or 6) cell-cell communication, to name a few. Yet, it is important
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to note that exposure to EDCs may influence tumorigenesis through both DNA-mediated
and non DNA-mediated mechanisms.
Mammary Gland Development and Correlation to Cancer
In the US, more money is spent towards the detection and treatment of breast cancer (~$16.5
billion in 2010 dollars) than any other type of cancer [18]. One of the reasons is that breast
cancer is not a single disease, but a heterogeneous and phenotypically diverse set of diseases
[19]. Several molecular subtypes exist [20–22], and each respond to treatment differently.
Numerous studies have been conducted in an effort to better understand the etiology of the
several types of breast cancer. Not only is breast cancer complex, but so is normal breast
morphology. Breast tissue consists of multiple cell types, which must remain in close
communication. Normal mammary gland growth involves intricate crosstalk between the
epithelium and the surrounding stroma, to balance proper proliferation/apoptosis and
remodel the gland at the different stages of life.
Rapid mammary gland development occurs in three distinctive life stages: fetal, peri-
pubertal, and pregnancy [23]. In girls, the fetal mammary bud begins to form late in the first
trimester of pregnancy. During the last few weeks of pregnancy, the nipple and the primary
epithelial ducts form and ducts branch outward into the stroma. Relatively little epithelial
growth is observed until around the time of puberty when the gland growth is influenced by
the release of pituitary and ovarian hormones. During thelarche, one of the earliest signs of
puberty, female breast tissue enlarges and grows outward, making it noticeable. At the same
time the mammary fat pad enlarges in size, and the rapidly extending epithelium form
bulbous or club-like structures at the duct ends, termed terminal ductal lobular units
(TDLU). The TDLU are structurally similar to terminal end buds (TEB) in rats and mice,
present during the same life stage. These structures are undifferentiated and highly
proliferative, and as such they are sensitive to the effects of carcinogens and other
chemicals. The breast reaches a static stage some time after first menstruation, changing
slightly with each additional menstrual cycle. Figure 2 demonstrates the progressive growth
of the mammary epithelium within the fat pad of the mouse until it reaches the adult resting
state. Thereafter, the gland remains in a fairly static stage throughout life, until a pregnancy
occurs. At this time, morphological maturation is achieved and the gland continues to branch
and fill with lobulo-alveoli to support the production and release of milk. EDC-induced
disruption of normal development at any and all of these stages can cause permanent
developmental abnormalities, impaired lactation, and influence risk for the development of
breast cancer. It is important to note that male breast development also occurs in utero, and
is halted in boys by the androgen surge that occurs just before birth. Anti-androgenic
chemical exposures in rodent models have caused reversal of that gender-specific response
[24–26]. It is important to note that EDC-induced changes affect risk for hormonally-
responsive mammary tumors, such as the common ER+/PR+ subtype.
The use of rodents in laboratory studies has advanced our knowledge about the mechanisms
controlling normal mammary gland growth, as well as fill knowledge gaps concerning
spontaneous and chemical-induced carcinogenesis. The 2 year bioassay, involving adult
exposure to test chemicals, provides evidence of spontaneous carcinogenesis (in the entire
body), whereas the use of a chemical carcinogen such as dimethylbenz-a-anthracene
(DMBA) following an early life chemical exposure tests the specific susceptibility of the
mammary gland to form tumors. It is important to emphasize that dose levels and timing of
exposure to EDCs may affect the severity, or lack thereof, of an effect on mammary gland
growth and consequently breast cancer risk [23]. EDC exposure can accelerate rodent
mammary gland growth leading to unbalanced or unchecked proliferation of the gland. For
example, prenatal exposure to DES accelerates mammary gland growth with increased
Macon and Fenton Page 4













lobular proliferation resulting in increased hyperplastic nests of epithelium and tumor
multiplicity, as well as decreased tumor latency [27, 28]. Compared to controls, a virgin
rodent with accelerated development of the mammary gland will have more TEBs compared
to terminal ducts at weaning (3 weeks of age), and rat weanlings may exhibit extensive
alveolar budding. As development progresses, exposed rodent mammary glands will exhibit
a greater number of lobules, possibly with greater complexity, than unexposed animals. Yet,
EDCs that cause delays in mammary growth can also increase sensitivity to carcinogens and
increase risk for breast cancer. Delayed development of rodent mammary glands often
manifests as decreased longitudinal growth of the epithelium and fewer TEBs compared to
controls at the time of weaning. These changes may also be present in adolescent animals;
fewer duct ends, decreased branching density and smaller gland outgrowth. At puberty,
delayed glands may have more TEB than controls due to the slower pace of development.
Although somewhat counter-intuitive, mammary gland growth delays can increase cancer
risk by prolonging the presence of carcinogen-sensitive structures, such as TDLU or TEBs.
Figure 3 demonstrates examples of accelerated and delayed mammary gland development,
compared to vehicle-treated controls, in the rat.
Although exposure to EDCs can increase breast cancer risk, some EDCs have been reported
to have beneficial effects and protect against the development of breast cancer (see
phytoestrogens). Exposure to EDCs can stimulate growth so that the gland is mature with a
high ratio of fully differentiated structures compared to immature or un-differentiated
structures or can reduce the proliferation and apoptosis ratio within the epithelium. As stated
before, the beneficial effects of EDCs are highly dependent upon exposure levels and timing
of exposure. Inhibition of mammary gland development early in life can be so severe that
the mammary epithelial tree does not form past a nascent structure, leaving little
proliferative potential [29]. In addition to reduced risk for mammary tumor formation, these
delays result in glands that are less responsive to ovarian and pituitary hormones,
consequently reducing the functionality of the gland. Severe inhibition of mammary
development has only been observed in rodents at high EDC exposures [30, 31]. For
humans, these elevated levels of exposure may not be reached except in rare cases of high
occupational or non-occupational accidental exposures (i.e. pollution). Yet, in wildlife and
domesticated mammals, excessive exposures that result in severely stunted glands diminish
sustenance to developing offspring, resulting in reduced postnatal survival because of
minimal/no milk production [32].
Although the ductal or lobular epithelia are often the sites of tumor production, mammary
stroma growth patterns can also influence breast cancer risk. The communication of the
multiple cell types in the mammary gland, i.e. stromal-epithelial interaction, is critical for
normal development throughout life [8]. Studies have linked increased stromal density in the
breast to later development of epithelial based mammary tumors [33]. When mammary
tumor tissues were separated into epithelial and stromal compartments, recombination of
normal epithelium with tumor stroma resulted in the growth of epithelial tumors while
recombination of tumor epithelium with normal stroma resulted in the growth of normal
tissue, indicating that stromal tissues have strong influences on overall gland growth and
tumor status [11]. Deleterious modifications to stromal tissues can occur along with
accelerated or delayed overall mammary gland growth and is another way EDC exposure
can influence the development of mammary tumors [16, 34, 35]. In fact, thickening of the
stromal compartment surrounding the epithelium has been found in the case of prenatal
Bisphenol A exposure in rats [34] and following prenatal exposure to perfluorooctanoic acid
in mice [36]. As expected, exposure to EDCs that alter mammary development may also
cause an array of detrimental health effects in other organs. Table 2 demonstrates a
multitude of reproductive/hormonal effects from a handful of EDCs that are known to affect
the mammary gland.
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Endocrine Disruptors and Breast Effects
Timing of exposure to EDCs in rodents and women determines how the mammary gland
may react to the exposure. This finding, and our current understanding of the various
subtypes of breast cancer, may provide insight to the way researchers address breast cancer
prevention. Although we review several EDCs here (and summarize their impact on breast
cancer in Table 3), many other examples are given in a review of EDCs by Rudel et al. 2011
[17].
Polycyclic Aromatic Hydrocarbons
Polycyclic aromatic hydrocarbons (PAHs) are a class of chemicals formed during the
combustion of many substances including coal, wood, gasoline, and food. Additionally,
PAHs are found in cigarette smoke (see Reynolds et al., this issue). These are highly stable
organic compounds that often have genotoxic and mutagenic properties. Due to these
properties, PAHs are considered carcinogenic, as they cause mutations which initiate and/or
promote the growth of tumors.
PAHs also have endocrine-disrupting properties and affect hormone signaling by binding to
estrogen receptors [37]. PAH-induced tumors regress in ovariectomized rats [38] indicating
these effects are hormonally regulated. One of the most notable PAHs shown to cause breast
cancer in animals is DMBA, which has been introduced as a mammary-specific carcinogen.
In laboratory studies, DMBA is often administered to rodents to determine the influence of
other chemicals on tumor latency and multiplicity.
PAHs are also found in food. 2-amino-1-methyl-6-phenylimidazo [4,5-b]pyridine (PhIP) is a
PAH found in well-done or chargrilled meats. This estrogenic compound is a mammary
carcinogen in rodents [39–41], but concerns have risen over the presence of PhIP induced
DNA adducts in human mammary glands [42]. Epidemiological studies report that women
that ate well done meat were more likely to have breast cancer than women who ate rare to
medium-well cooked meats [43]. Due to their mutagenic properties, the effects of PAH
exposure is not limited to the mammary gland.
Bisphenol A
Bisphenol A (BPA) is a high production-volume chemical that is found in a variety of
consumer products including plastics used to make drinking containers, epoxy resins that
line metal food and drink cans, dental sealants and paper receipts [44]. Through physical
manipulation or contact, BPA can leach from these products leading to unintended
exposures. As a result, BPA contaminates food and water, with oral consumption being the
main route of exposure to humans. Following oral exposure, BPA is metabolized to its
glucuronidated-conjugate [44, 45]. Recent attention has been paid to BPA and its potential
effects on development. It can be found in plastics used to make baby bottles and children’s
toys, is found in the serum of infants and children, and has been linked to obesity [46]. It is
one of the few EDCs discussed that does not persist in organisms, i.e., it has a short half-life
(5.3 h in adults), yet internal serum levels may remain steady due to continual exposure [45].
It also has structural similarity to estradiol and, like DES, it demonstrates estrogenic
properties [47, 48].
Since BPA mimics estrogen, exposures to this compound can cause endocrine disruption. In
vitro studies indicate BPA binds to estrogen receptors (ERs; α and β) [48], estrogen receptor
related gamma (ERRγ), and the G-coupled protein receptor, GPER/GPR30 [49]. BPA
elevates testosterone, pregnenolone, and estradiol in rat ovarian cell cultures [50]. Adult
male rats orally exposured to 200 mg/kg BPA had elevated relative testicular, seminal
vesicles, and prostate weights, with decreased sperm production and motility [51]. These
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same oral adult exposures had no effect on female reproductive organ or estrous cycle, but
did elevate serum estradiol and androstenedione [51]. Developmental exposures to BPA
affect neuroendocrine signaling by increasing ERα and ERβ in the hypothalamus [52]. BPA
disruption of the endocrine system also plays a part in altered mammary gland growth.
In rodents, prenatal exposure to BPA has been shown to accelerate mammary gland growth.
Mice given BPA through subcutaneous implanted osmotic pumps had mammary glands with
hyperplasic epithelial ducts and a beaded appearance [47]. Munoz de Toro [53] also found
that prenatal exposure to BPA in rats (via minipump) induced mammary gland growth
acceleration. In another study, prenatal exposure to 25 or 250 µg BPA/kg in CD-1 mice
resulted in glands with increased mature structures (alveolar buds and terminal ducts) and
increased stromal cell proliferation compare to controls at 6months of age [16], indicating
that prenatal BPA accelerated MG maturation. Although in the adult gland it was clear that
BPA stimulated accelerated development following early life exposure, at 1 month of age,
mice in the 250 µg/kg group displayed mammary growth patterns indicative of delayed
development, with reduced ductal elongation, reduced stroma proliferation, and fewer TEBs
compared to controls. These results are similar to those observed previously for other
estrogenic compounds [54]. These findings highlight the importance of examination of
multiple time-points following chemical exposure and shows how initial growth delays can
eventually result in rampant cellular proliferation for estrogenic compounds.
The relevance of the earlier animal studies using minipumps has been questioned since
human exposures are primarily oral (metabolized differently) and circulating blood levels
were not provided, limiting cross-species extrapolation. However, fetuses are exposed to
BPA through the maternal circulation regardless of mothers’ route of exposure, thus
dampening this argument, especially as it pertains to low-dose prenatal exposure studies. To
further address these issues, recent animal studies have administered BPA in the water
supply or through oral gavage. Using the more translatable route of exposure, neonatal BPA
exposures (25 and 250 µg/kg) in rats resulted in numerous TEBs which had a high
proliferative index [55]. Similar mammary gland growth accelerations were observed in
rhesus monkeys prenatally exposed to oral BPA, creating human relevant unconjugated
BPA serum levels [56]. To determine whether or not mammary defects caused by BPA were
related to cancer risk, prepubertally exposed Sprague Dawley rats were given DMBA at 50
days of age. This dual exposure increased tumor multiplicity and reduced tumor latency in
250 µg BPA/kg BW-treated animals. BPA treatment increased proliferation and reduced
apoptosis compared to controls [55, 57]. Prenatal exposures to BPA also were found to
increase mammary tumor multiplicity and decrease tumor latency. However BPA shifted the
time at which the mammary gland was most susceptible to DMBA possibly by altering the
timing of TEB abundance in the gland [55, 58]. These data indicate that oral prenatal BPA
exposure, at low levels, resulted in mammary gland aberrations that affected carcinogen
susceptibility, in addition to the already strong data from mini-pump delivery studies in rats
and mice. Furthermore, recent evidence suggests that BPA persistent effects are likely due to
epigenetic alterations [59].
Exposure to BPA during adulthood has also been found to influence cancer risk in rodent
models. Using a transgenic MMTV-erB2 mouse model, female mice were exposed to
drinking water with 2.5, 25, 250, 2,500 µg BPA/L from PND 56–122 or PND 56–252. At
PND 112, the mammary glands of BPA exposed mice had a higher proliferation index when
compared to controls. However, the highest exposure of BPA (2,500 µg/L) resulted in
increased apoptotic index [60]. At PND 252, only exposures to the low doses of BPA (2.5,
25) resulted in statistically significant increase in mammary tumor multiplicity and reduced
tumor latency, yet there was no increases observed in the 3 higher doses [60]. Other studies
have found similar effects that do not follow typical dose response curves, which creates
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some difficulty in extrapolating data to humans. These data taken together suggest that low
doses of BPA have adverse effects on the mammary gland distinct from those of high doses.
This could be due to separate/multiple signaling paths being triggered at various dose levels
[58].
Organochlorine Pesticides
As the name suggests, organochlorines are chlorinated hydrocarbons and they are typically
used as pesticides—either insecticides or herbicides. The insecticides were designed to be
neurotoxins, and the herbicides are effective at disrupting photosynthesis, but they have also
been found to have effects on the reproductive system, including the mammary gland.
TCDD—One of the most infamous organochlorines is 2,3,7,8-tetrachloridibenzo-p-dioxin
(TCDD or dioxin). TCDD is a polycyclic chlorinated hydrocarbon that is a pollution product
of combustion and manufacturing chemicals. Agent Orange, the herbicide used by the
United States Army in the Vietnam War, was found to be contaminated with TCDD. TCDD
can be found in the soil and water, and due to its lipophilic properties and extensive half-life
of approximately 7–8 year in humans [61], TCDD bioaccumulates in animals and the
environment. TCDD binds to the aromatic hydrocarbon receptor (AhR) [62] and has anti-
estrogenic properties. There are several other environmental contaminants that bind to AhR
and their hazard levels are based on their effects relative to TCDD or the toxic equivalency
factor [63].
TCDD has several endocrine disrupting effects such as reduced estradiol production and
elevated ER mRNA expression in uterine, ovarian, and hypothalamic tissues of rats [64]. A
single prenatal TCDD exposure of 1 µg/kg by gavage in female rats delayed timing of
vaginal opening and disrupted normal estrous cyclicity [65–67]. Adult exposure to dioxin
also reduced uterine-ovarian weights [68]. Endocrine disruption in male rats from TCDD
exposure has been shown to reduce sperm production and delay preputial separation, a
marker of sexual maturation [69]. Although TCDD binds to AhR, dioxin can increase
aromatase activity, the enzyme that irreversibly converts androgens into estrogens, and can
consequently elicit effects on androgen- and/or estrogen-dependent organs [70].
From animal studies, it has also been found that TCDD exposure delays mammary gland
growth. A single prenatal exposure to TCDD via gavage causes severe retardation of the
mammary gland resulting in numerous immature undifferentiated structures [65, 66].
However, the timing for that exposure is critical and must be at the time of mammary bud
development in utero, for the most deleterious effects to be observed. Prenatal exposure to
TCDD via gavage accompanied by DMBA exposure in young adulthood (PND 50) resulted
in increased mammary tumor formation and reduced tumor latency compared to controls
[66]. Population studies investigating the effects of high TCDD exposure in Seveso, Italy
found that women in the area had an increased risk for breast cancer [71] although a follow-
up evaluation of that population found no association between TCDD exposure and breast
cancer incidence or mortality [72]. Many of the girls that were exposed to high levels of
TCDD had not reached postmenopausal ages (age at most risk for breast cancer in normal
population) by the time of the data analysis, and it is possible that the reported results did
not reflect the actual effects in women. Therefore, it is important that there is a follow-up
study to determine whether these women develop breast cancer to accurately assess the
health outcome related to TCDD exposure. Occupational exposure to dioxins in a Hamburg,
Germany, pesticide plant resulted in significantly increased breast cancer mortality among
women workers [73].
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PCB—Polychlorinated biphenyls (PCBs) are a class of compounds that are plasticizers,
solvents, and other industrial chemicals. These chemicals have high lipophilicity and
bioaccumulate in animals and the environment. These chemicals are stored in adipocytes in
the body, and as a result are transferred into breast milk. PCBs have long half lives in
humans [61]. In addition, PCBs can also bind to the AhR, and have similar effects to that of
TCDD. Not all PCBs act alike; some congeners have anti-androgenic and mixed estrogenic/
anti-estrogenic effects, while many of them also alter thyroid activity.
One of the most studied PCBs, 3,3,4,4,5-pentachlorobiphenyl (PCB 126), is classified as a
“dioxin-like compound” and has a toxic equivalency factor of 0.1, making it 10 times less
toxic than TCDD [74]. Prenatal exposure to PCB126 induces mammary developmental
delays (designated by decreased alveolar budding) [75] which at a high dose (7.5 µg) has
been shown to reduce carcinogen-induced tumors [29] yet increase tumor weight and tumor
proliferation index at a lower dose (250 ng). In addition exposures at these levels also
reduced serum estradiol [75]. In vitro studies with mammary tumor cell lines demonstrate
that PCB 126 and other PCBs inhibit estradiol-stimulated tumor cell growth [76]
highlighting the anti-estrogenic effects of these chemicals. In a review of epidemiology
studies, only a few case–control studies found a positive association between PCB exposures
and elevated odds for breast cancer [77].
DDT and DDE—Dichlorodiphenyltrichloroethane (DDT) is a synthetic industrial and
household insecticide whose widespread use as a mosquito repellent and its long half-life
made it a prominent environmental contaminant. Although DDT consequently helped lower
incidence of malaria and typhoid, its use was banned in the US in 1972 for its effects on the
environment and potential effects on human health [78]. Like most insecticides, DDT
demonstrated neurotoxic effects, but DDT and its metabolites also caused an array of
reproductive and developmental effects and partitioned into breast milk [79].
DDT and its main metabolites dichlorodiphenyldichloroethylene (DDE) and
dichlorodiphenyldichloroethane (DDD) have endocrine disrupting properties. Some of the
metabolites have estrogenic properties (o,p’-DDT and o,p’-DDE [1,1-dichloro-2-(o-
chlorophenyl)-2-(p-chlorophenyl) ethylene), while others have anti-androgenic properties
(p,p’-DDE [1,1-dichloro-2,2-bis(p-chlorophenyl) ethylene) [80].
In a 2012 study by Johnson and colleagues, HER2/Neu transgenic mice were implanted with
pellets that released p, p’-DDE or o,p’-DDE and while neither metabolite increased
mammary tumor multiplicity, both decreased mammary tumor latency [80]. In previous
studies, o,p’-DDE has been shown to enhance mammary epithelium growth and increase
epithelial cell proliferation index [68], as well as increase mammary tumor cell proliferation
[81]. There are few epidemiological studies that have found positive associations between
DDT or its metabolites in serum and increased risk for the development of breast cancer.
This is primarily due to the fact that those studies evaluated serum levels of DDT/DDE in
women around the time of cancer diagnosis which cannot take into consideration exposure
levels in conjunction with tumor latency. However, in a prospective case–control study, girls
exposed to higher DDT/DDE levels were more likely to develop breast cancer than those
with lower exposures, and risk increased with younger age at exposure [82]. For this study,
the blood/-serum samples were collected during periods of high and unregulated DDT
exposures in the US. Moreover, younger girls (age <14) with higher DDT/DDE blood levels
were more likely to develop breast cancer than girls exposed at age ≥14 [82] which
highlights the sensitivity of the mammary gland around puberty and underscores the need to
consider age of exposures for risk assessments.
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Atrazine—Atrazine is a high use organochlorine herbicide utilized to control weeds in
various farm/food crops. Atrazine and its metabolites are found in water, soil, plants, and
animals [83]. Even though atrazine has a short half-life of ≤1 day in rodents, oral exposures
are reported to induce multiple reproductive and developmental effects [84].
In the past 30 years, safety regulations have been placed on atrazine use due to its
persistence in the environment and its proven role as an endocrine disruptor in rodents and
amphibians [85]. In rats, atrazine exposures reduce the normal surge of luteinizing hormones
in female adults via altered hypothalamic signaling [86]. Adult exposure in male rats results
in increased relative testicular and epididymal organ weights with reduced sperm production
and reduced androgen hormones in rats [51]. It is also thought that atrazine-induced
alterations in maternal hormone signaling may play a role in prostate inflammation of
developmentally exposed male Long Evans and Wistar rat offspring [87–88].
Prenatal exposure to atrazine alone or as a metabolite mixture has also been shown to deter
normal mammary gland development in Long Evans female rats, resulting in glands with
more TEBs, sparse branching patterns and impaired growth compared to controls at vaginal
opening and young adulthood [87, 89]. Atrazine is not classified as a direct carcinogen or
mutagen [90, 91], but lifelong dietary exposures have been shown to increase spontaneous
mammary tumor development in rats [90, 91]. There are species and strain differences in
effects related to atrazine exposure. Chronic dietary atrazine exposure in Sprague Dawley
rats increased the incidence of adenocarcinomas in exposed females compared to controls
[90] yet there was no effect on tumor incidence in F344 rats in another study [92]. In
addition, atrazine exposure following carcinogen-induced tumor formation increased tumor
incidence in human c- Ha-ras proto-oncogene transgenic rats [93]. A full review of atrazine
carcinogenicity studies can be found in Stevens et al., 1999 [91]. A review of the one known
mode of action for atrazine-induced tumor development—hastened reproductive senescence
—was not deemed human relevant, therefore atrazine is not currently regarded as a possible
human carcinogen by risk assessors [85].
Epidemiological studies that estimate human exposures from agricultural atrazine use found
little if any association between atrazine and breast cancer, however it has been difficult to
assess actual exposure of women to this chemical over their lifetime or during sensitive
windows of breast development due to the lack of sensitive measurement protocols.
Longitudinal epidemiological studies are needed in farming communities, especially in those
communities raising corn as a major crop, to truly evaluate early life exposures and late life
effects of atrazine and its metabolites.
Vinclozolin
Another chemical with both endocrine disrupting properties and reported mammary gland
effects is (3-(3,5-dichlorophenyl)-5methyl-5-vinyl-oxa-zolidine-2,4-dione), vinclozolin.
This lipophilic pesticide is used on fruits and vegetable crops to protect against the growth
of several fungi. It is also used on golf course turf [94]. Exposure to vinclozolin occurs
mainly through eating foods with residual contamination and drinking contaminated water.
Since vinclozolin is lipophilic, it is likely to bioaccumulate in wildlife and potentially can be
found in breast milk. In addition, a recent study has found measurable concentrations in cord
blood [95], suggesting that vinclozolin is transferred to the fetus. Vinclozolin is metabolized
to 2-[[(3,5-dichlorophenyl)-carbamoyl]oxy]-2-methyl-3-butenoic acid (M1), and 3′,5′-
dichloro-2-hydroxy-2-methylbut-3-enanilide (M2) with the metabolites being more
biologically active than the parent compound [96].
Vinclozolin’s endocrine disrupting properties were first noted in the male reproductive
system [97, 98]. Several studies have documented the anti-androgenic effects of vinclozolin
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and its metabolites. Prenatal vinclozolin exposure in rats resulted in reduced prostate weight
and anogenitial distance, retention of nipples and areola, hypospadias, and undescended
testicles, while adult exposures had far less severe effects [24–26, 51]. In male rats,
vinclozolin elevated serum androstenedione, testosterone and LH, and reduced estradiol
levels [51]. Multigenerational exposure to vinclozolin elevated the prevalence of a myriad of
tumors in males including tumors of the prostate, testis, and immune system [99]. In vitro
studies indicate that vinclozolin and M2 are antagonists for mineralocorticoid receptor and
PR and all three are weak agonists of both ERs [96]. A recent evaluation of pesticides in
human cord blood and birth weight found that vinclozolin is statistically associated with
reduced birth weights (0.18 ng/ml geometric mean) [95]. Some vinclozolin effects are
epigenetic in nature [99].
Vinclozolin also affects the female reproductive system. Adult exposures in female rats lead
to elevated uterine and adrenal relative weights, elevated serum LH and androstenedione,
and increased ovarian androstenedione and estrone [51]. While early exposure to vinclozolin
delays puberty in males [24], it is not associated with precocious or delayed puberty in
females in rodents or humans [100, 101]. In addition, a multigenerational rat study using 100
mg/kg vinclozolin found mammary tumors only in females offspring, however the incidence
of these tumors was low and it was unclear whether this endpoint was statistically
significant compared to controls [99]. Recent studies indicate that vinclozolin has effects on
mammary gland development. In a study by Saad et al. (2011), pregnant Wister Han rats
were orally given low level vinclozolin (1 mg/kg) daily from GD 1 through PND 21 [100].
Morphological evaluations of whole mounts of mammary glands on PND 35 showed
increased epithelial branching density in the vinclozolin-treated group compared to controls,
yet there were no statistically significant changes in counted mammary structures (i.e.,
TEBs, TD, AB). At PND 50, there were increased TEBs in vinclozolin-treated rats
compared to controls while there were no differences in TDs or ABs [100]. In addition,
vinclozolin exposure increased areas of hyperplastic ducts, Ki67 gene expression, and
stromal-ductal density at PND 50. There were no differences in ER or AR gene expression
compared to controls when evaluated by PCR.
Additionally, this study also investigated the effects of vinclozolin with concomitant
genistein exposure. Exposures to the antiandrogenic and estrogenic compounds resulted in
precocious puberty and accelerated MG growth. These alterations in growth presented as
increased epithelial branching, increased hyperplastic ducts, increased proliferation, and
increased stromal-ductal density at PND 35. At PND 50, exposure to the mixture increased
hyperplastic alveolar structures in treated glands compared to controls. Importantly, the
resulting effects from exposure to a mixture of vinclozolin and genistein were more
pronounced compared to changes with vinclozolin or genistein alone. These data suggest
that co-exposure of vinclozolin and genistein act together to synergistically affect MG
growth which may potentially lead to increased mammary tumor formation in rats. While
the dose of genistein used in this study is well below levels from consumption of soy-based
formula, the vinclozolin levels used are higher than those from dietary exposures. Further
studies are needed to fully characterize the effects of vinclozolin on mammary gland
development and to determine its effects on breast cancer risk.
Phthalates
Phthalate esters are widely used as plasticizers and are added to polymers such as polyvinyl
chloride (PVC) to increase pliability. Concern about phthalate exposure has grown due to
their presence in plastic baby bottles, children’s toys, various cosmetics and medical tubing.
Phthalates easily leach from plastics and PVC due to normal wear and tear and physical
manipulation and residues can be found in household dust [102]. As a result, exposure to
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phthalates occurs mainly through inhalation and oral exposure. Compared to adults, infants
and children have higher exposure levels to phthalates
Phthalates have been found to have an array of effects on both the reproduction and
development of humans and rodents, primarily mediated by influences on the endocrine
system. Exposure to phthalates in rodents reduces estradiol production, delays puberty, and
reduces fecundity with reduced implantation sites, increased fetal resorptions, decreased
fetal birth weights, nipple retention in males, and increased malformation in offspring [50].
Epidemiological studies have found that boys born to mothers with higher urinary phthalate
metabolites had shorter anogenital distance than boys born to mothers with lower urinary
phthalate metabolites [103]. In rats this finding was confirmed [104] and prenatal and
preconception exposure to phthalates was associated with developmental and testicular
toxicity of offspring [105–108]. In women, exposure to phthalates is associated with
endometriosis risk and in animal studies has shown to alter mammary gland development
[109].
In rats, prenatal exposure to butyl benzyl phthalate (BBP) causes slightly accelerated
mammary gland growth but delays the onset of puberty [110, 111]. Glands from
developmentally-exposed female offspring had increased proliferation index in TEBs at
PND 21 and 35 [112] suggesting that BBP exposure could increase sensitivity of the
mammary gland to chemical carcinogens. A two-year BBP feeding study in adult rats
reported decreased mammary fibroadenomas [113]. In Mexican women, higher urinary
concentrations of monoethyl phthalate were associated with a two-fold increase in breast
cancer risk [114]. In the same study, higher concentration of more bulky phthalates,
monobenzyl phthalate and mono(3-carboxypropyl) phthalate, were inversely associated with
breast cancer risk [114]. It is proposed that phthalates affects mammary gland growth
through epigenetic changes [115] and importantly, phthalate exposure counteracts the effects
of tamoxifen on mammary cancer cells [116]. The effects of other EDCs on breast cancer
chemoprevention are just beginning to be reported.
PFOA—Perfluorooctanoic acid (PFOA) is a chemical that has endocrine disrupting
properties and can affect mammary gland growth. PFOA is a synthetic surfactant that is used
in the production of fluorotelomers commonly used in non-stick and stain-resistant products,
flame resistant foams, dental products, and lining of popcorn bags. PFOA is detected in all
Americans sampled [117, 118], and human exposure occurs through use of aforementioned
products, household dust, and contaminated drinking water. Additionally PFOA binds
proteins, so is transferred to the offspring via the placenta and breast milk. In adult humans,
PFOA is slowly eliminated from the body with a half-life of 3.8 years [119]. PFOA
exposure in rodents is commonly associated with liver toxicity, but PFOA also causes
endocrine disruption and reproductive and developmental toxicity.
PFOA is considered an EDC due to its affects on the immune system, thyroid, and
metabolism. Exposures to PFOA modulate immune response in children and have been
linked to altered cholesterol and altered thyroid function [120]. Although this linear
halogenated hydrocarbon has little physiochemical properties with other EDCs and no
structural similarity with estradiol, PFOA has been shown to bind to ER and estrogen
receptor response elements [121]. From in vitro studies, PFOA has been shown to be both
estrogenic and conversely anti-estrogenic when incubated with estradiol [121]. In mouse
studies, prenatal, neonatal, and peripubertal exposures have shown to delay onset of puberty
or vaginal opening in females [122–124]. Uterotrophic studies show increased uterine
weights at low doses (0.01 mg/kg) [125]. Peripubertal PFOA exposures indicate there are
strain differences in uterine effects [123]. Peripubertal exposure to 1–10 mg/kg PFOA in
Balb/C mice resulted in reduced uterine weights, while C57Bl/6 mice had increased uterine
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weights at 1 mg/kg and reduced uterine weights at 10 mg/kg. One prenatal study has shown
that PFOA accelerates puberty in young male mice [122]. Two year exposures studies to
PFOA in male rats leads to increased Leydig Cell tumors with reduced circulating
testosterone [126], suggesting PFOA has anti-androgenic properties. A full review of the
endocrine disrupting properties of PFOA can be found in White et al. 2011 [126].
There has been only one published animal study that has investigated the effects of chronic
PFOA and evaluated mammary tumor formation [127]. The significance of this study, and
others, has been criticized due to the use of female rats as the animal model. Female rats
eliminate PFOA at extremely high rates (a few hours) while female mice and women
eliminate PFOA at a much slower rate (21 days and 3.8 years, respectively) [119, 128]. As
mice (not rats) and humans exhibit no sex differences in PFOA elimination rates, mice are
used as a more appropriate animal model for evaluation of PFOA toxicity. To date, there are
no published 2 year PFOA exposure studies nor PFOA and DMBA-induced carcinogenicity
studies in mice. Most occupational studies solely report on male health outcomes due to
small population of female workers. Epidemiology studies would suggest that PFOA may
actually lower breast cancer risk, as it has been positively associated with delayed puberty in
girls [129] and early menopause [130]: two factors that are negatively associated with breast
cancer risk. In addition, recent studies indicate high serum PFOA is also associated with
preeclampsia, pregnancy-induced hypertension, which is negatively associated with breast
cancer [131]. However, a recent study of Inuit women found a positive association between
perfluorinated compounds along with other persistent organic chemicals and breast cancer
risk, suggesting that PFOA and other EDCs may affect disease development in this small,
highly exposed population [132].
Animal studies with more detailed examination of effects on mammary gland growth agree
with the Inuit data, and suggest that PFOA exposure may increase susceptibility for
development of mammary tumors. Prenatal exposure to PFOA has been shown to delay
mammary epithelial development [35, 36, 124, 133]. Restricted and cross-foster exposure
studies in CD-1 mice (Fig. 4) showed delayed mammary gland growth for all PFOA-treated
groups assessed by developmental scoring [124]. These delays were characterized by
reduced ductal elongation and side-branching into adulthood. Timing of appearance of TEBs
is shifted with PFOA exposure as there are fewer TEB at PND 22, but more at PND 42,
when compared to controls. Abnormal mammary gland maturation persisted at 18 months in
glands exposed to 5 mg/kg with reduced epithelial density and increased stromal density, a
factor associated with increased breast cancer risk [33, 35]. In addition there were areas of
epithelial hyperplasia in PFOA-treated mice at 18 months. Similar effects were observed
using lower PFOA doses (0.01 –3 mg/kg) [124]. In those studies, full gestational exposures
resulted in extended presence of mammary TEBs at doses 0.3–3.0 mg/kg, suggesting the
PFOA exposure may increase susceptibility to carcinogens. Late gestational exposure to
0.01–1 mg/kg PFOA also resulted in significant mammary developmental delays [124].
These delays were present at serum PFOA concentrations in mice that overlap with those
observed in young children living in highly exposed areas in the US [124, 134]. These
studies suggest that in utero and lactational exposure to PFOA delay development and could
increase the susceptibility of the mammary gland to carcinogens.
Like other EDCs, there are differences in effect based upon timing of exposure. Exposure to
PFOA from puberty into young adulthood resulted in reduced ductal elongation in Balb/C
(2.5–10 mg/kg) and C57Bl/6 mice (7.5–10 mg/kg), decreased side branching in Balb/C mice
(2.5–10 mg/kg) and C57Bl/6 mice (7.5 mg/kg) and increased side branching in C57Bl/6
mice (5.0 mg/kg) [123, 135]. This single stimulatory effect in the 5 mg/kg PFOA-treated
C57Bl/6 mice may be caused by a concomitant rise in circulating progesterone [136].
PFOA-treated C57Bl/6 adult glands displayed elevated ERα protein expression in the
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epithelium compared to controls [136]. Furthermore, PFOA-induced systemic
immunomodulation and elevated production of reactive oxygen species from mitochondrial
damage [137] may increase susceptibility of mammary tissues to chemical carcinogens and
remains to be tested.
Phytoestrogens
The chemicals that have been discussed thus far are synthetic compounds that disrupt the
endocrine system by mimicking or inhibiting endogenous hormones. However, there are
naturally-occurring chemicals that also mimic or mask effects of endogenous hormones.
Phytoestrogens are naturally occurring estrogens that are found in plants. There are some
that believe that phytoestrogens have beneficial effects to treat and/or prevent breast cancer.
Yet, there are reported negative effects associated with phytoestrogens. As with many of the
other compounds, the difference between beneficial and detrimental health effects depends
on dose and timing of exposure.
Genistein—In recent years, the perceived health benefits of consuming soy due to the high
isoflavones and their estrogenic properties has increased in popularity. Asian women have
lower lifetime breast cancer rates compared to Caucasian American women [138, 139], and
some speculate that their high-soy based diet has protective effects against mammary
tumorigenesis. Genistein is the most abundant isoflavone in soy along with daidzein [140].
As it is a polyphenol, genistein shares structural similarities with estradiol and has been
shown to behave like an estrogen. Some studies have shown that a high soy diet/
supplementation reduces breast cancer risk in women [141–143]. In rats, exposure to
isoflavones beginning in utero to adulthood has been shown to protect again carcinogen-
induced mammary tumors [144, 145]. Upon closer evaluation of the influence of timing of
exposure on effects of genistein in rodent models, prepubertal exposure appeared to have the
most beneficial effects against carcinogen-induced mammary tumorigenesis, compared to
perinatal or adult only exposures [146–149]. Glands from peripubertal genistein-treated rats
demonstrate accelerated growth compared to controls with fewer TEBs and more
differentiated ends. Yet when rats were treated with genistein during prenatal or adult time-
points, the induced morphological changes had no protective effects on MNU-induced [146]
or DMBA-induced mammary gland tumors [147]. Genistein also appears to have some
chemotherapeutic properties when given after tumor initiation and promotion. Genistein
given in rats with tumors was shown to stabilize DNA in mammary epithelial cells of the
normal tissue. It is thought that genistein protects against tumor growth via upregulation of
the tumor-suppressor protein PTEN [147].
Genistein exposure can also leave the mammary gland more susceptible to spontaneous
tumorigenesis. In a multigenerational study conducted by the National Toxicology Program
(2008), developmental genistein exposures in rats increased incidence of adenomas and
adenocarcinomas collectively compared to controls [150]. In addition, low-levels of
genistein cancel out therapeutic effects of tamoxifen in breast cancer cells. The increased rat
mammary tumor incidence from lifetime genistein exposure is inconsistent with the
proposed protective effects of high genistein diets in Asian women and resulting low breast
cancer rates. However genistein is just one component of soy and studies have found
differences between using a mixture of isoflavones versus genistein exposure alone [151].
These adverse effects are not exclusive to females, as mammary ductal hyperplasia has also
been observed in males. In two multigenerational studies, dietary genistein increased ductal
hyperplasia in male rat offspring [150, 152]. The mammary gland was reported to be the
most sensitive tissue affected by genistein in males. Although this particular effect has not
been observed in human males, many fear the impact of additional estrogen-like compounds
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on the development of young boys, as males appear to be more sensitive to the effects of
some EDCs.
Resveratrol—Resveratrol (RES) is a polyphenol, like genistein, that can be found in
grapes, red berries, and red wine. It is estimated that human exposures to RES occur most
from the consumption of red wine as there is approximately 1.4 mg RES per glass
(calculated from [153]). Numerous studies have linked moderate consumption of red wine to
better health outcomes such as: reduced risk of cardiovascular disease, stronger immune
system, protection against memory loss, and prevention against the development of several
cancers, including breast cancer [154]. These beneficial effects are proposed to be due to the
antioxidant properties of RES.
The polyphenol has some structural similarity to estradiol and has endocrine disrupting
properties. For instance, RES treatment of ovarian thecal cells in culture caused elevated
androstenedione and androsterone production, with no effect on progesterone [155]. Prenatal
exposure to RES in Sprague Dawley rats increased ovarian weight in ovariectomized adult
females and reduced testicular weight and plasma testosterone in adult males [156]
demonstrating that RES can act as both an estrogen receptor agonist and antagonist,
depending on the target tissue.
Studies in animals support these findings and have shown that RES is protective against
mammary tumorigenesis [147, 157–160]. Lifetime exposure to RES in rats beginning at
birth was shown to accelerate mammary gland growth and differentiation compared to
controls and reduced susceptibility to carcinogen-induced mammary tumors [147]. RES-
treated glands were found to have lower proliferative index and a higher apoptotic index in
the mammary epithelial cells compared to controls [147]. Adult only oral exposures to RES,
which has better translation to human exposure patterns, in HER-2/neu transgenic mice also
demonstrated the beneficial effects of RES exposure [158], as the tumor prone mice treated
with RES displayed a longer latency to tumor when compared to controls. RES treatment
also reduced the metastatic capacity of these tumors by increasing apoptosis of tumor cells
[158]. Moreover, in vitro studies have demonstrated that RES has antitumor initiation,
promotion, and anti-mutagenic properties which were attributed to its inhibitory effects on
cyclooxegenase [160]. Thus, RES may be one of the only EDCs that has primarily beneficial
effects on the mammary gland, as related to breast cancer risk.
Zearalenone—Zearalenone (ZEA) is a mycotoxin that is produced by the fungus
Fusarium. This mold often grows on plants and crops such as oat, barley, corn, wheat, and
rice. ZEA can also contaminate the soil that the plants grow in, and the animals that eat the
plants (livestock) [161, 162]. ZEA and its metabolites have some structural similarity to
estrogen and have been shown to bind to estrogen receptors [162]. Since ZEA is found on
plants and has estrogenic properties it is often considered a phytoestrogen.
A study of mice exposed to ZEA in utero produced female offspring with accelerated
vaginal opening timing, increased estrous cycle length, and early mammary gland
maturation [157]. In rats, prepubertal exposure to ZEA was shown to reduce carcinogen-
induced mammary tumors [163], while prenatal exposure had no effects on tumor incidence
[164]. Mammary glands of rats exposed to ZEA during puberty had fewer TEBs and more
mature structures [163] which reduced the susceptibility of ZEA-treated glands to
tumorigenesis. In vitro studies have shown biphasic effects of ZEA, with low doses
promoting breast cancer cell growth and high doses increasing apoptosis and cell cycle
arrest [165].
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ZEA contamination of food systems has because a concern for humans. Several early studies
have linked ZEA exposure with precocious puberty in girls based on unsubstantiated
evidence [166, 167]. A recent study measured urinary mycoestrogens in New Jersey girls
and found an inverse association between urinary mycoestrogens and age at thelarche, or the
beginning stages of breast development, as well as a negative association between ZEA
levels and height [168]. As these findings are inconsistent with the data from animal studies,
more population studies are needed to determine the influence of ZEA on human mammary
gland growth and potential breast cancer risk.
Concluding Remarks
The dynamic signaling of the endocrine system makes it highly susceptible to influences
from exogenous chemicals. Since the endocrine system regulates and controls multiple
functions within the body, EDCs have the ability to greatly impact health outcomes. The
endocrine system plays an important part in timing of puberty and menopause, obesity,
breast density, and immune function, all factors which influence breast cancer risk.
Additionally, as presented, EDCs can alter mammary gland development potentially
increasing susceptibility to chemical carcinogens or spontaneous tumorigenesis. Therefore it
is important to understand the correlation between EDC exposure during different critical
windows of mammary gland development and breast cancer risk.
Understanding mechanisms of mammary gland development in laboratory animals has led to
significant insights into the general role(s) of EDCs on mammary gland development and
thus mammary tumor formation. However, there are still many gaps that can be addressed
with further studies. Despite the impact that breast cancer poses to women and our health
care system, mammary gland evaluation, breast cells, and lactation assessments are often
excluded from routine health hazard assessments in industry and government-based
chemical testing studies. There is a need to include mammary gland data in chemical hazard
and risk assessments. In order for this to be accomplished, it is important that there are
methods developed for evaluation of mammary growth patterns and their relation to health
outcomes such as changes in functionally capacity or neoplastic transformations.
To investigate the influence of EDC exposure and avoid waiting for 2 year rodent cancer
bioassay results for tumor development, many animal studies follow the experimental design
of EDC exposure (acute or chronic) followed by acute carcinogenic exposure. This model is
effective for a hazard assessment of these chemicals but chronic exposure to low doses of a
carcinogen may be more reflective of human exposure to classical chemical carcinogens. In
addition utilizing this type of experimental model would address species specific and
interspecies differences in timing of puberty as well as timing of mammary gland
maturation. Linking early life adverse outcomes, such as retardation or acceleration of
mammary development, to later life cancer risks would strengthen the use of whole mount
analyses in test guidelines on new or replacement chemicals.
Population studies on EDCs and other chemicals often correlate internal dosimetry, such as
serum concentrations, to health outcomes without the ability to determine causation. Animal
studies can dose with specific exposures (thus knowing causation), but often do not include
internal dosimetry, making it difficult to interpret data for the characterization of risk to
humans. There is need to bridge that transdisciplinary research gap. For this to be achieved,
inclusion of more time-points during stages of mammary gland development, along with
blood collection for dosimetry will help to understand the transition from normal to tumor
development. In addition, relatively little is known about how EDCs act together. It is
possible that the negative effects of one EDC are balanced by beneficial effects of another or
chemicals may act together to heighten the impact of their effects. Co-exposure with
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prevalent dietary EDCs such as genistein, or altered fat-content diets, would resemble
exposures that likely occur in average human life. A comparison of the effects from
mixtures relative to the effects of individual exposures would reveal a glimpse into true
human exposures and their resulting effects on health outcomes. Future studies must
consider determination of mechanisms of action for EDCs if we are to begin preventing
breast cancer.
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Endocrine tissues and their corresponding secreted hormone that influence mammary gland
growth or function. GH= Growth Hormone; EGF= Epidermal Growth Factor. (Modified and
republished with permission of Annual Reviews, Inc., from Ref [8]; permission conveyed
through Copyright Clearance Center, Inc.)
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Typical trajectory of mammary gland development in the CD-1 mouse from neonate to
young adult. PND = Postnatal Day. Carmine-stained whole mount mammary gland samples
were prepared using the NTP Animal Studies Protocol; Section XIII, Appendix 6, Section E.
http://ntp.niehs.nih.gov/ntp/Test_Info/FinalNTP_ReproSpecsMay2011_508.pdf
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Examples of accelerated development (right) and delayed development (left) compared to a
representative vehicle-treated control mammary gland at the time of weaning in the Long
Evans rat. Carmine stained whole mount mammary gland. Specific examples of EDC effects
in Table 2
Macon and Fenton Page 29














Permanent PFOA-induced mammary gland delays following oral prenatal/neonatal
exposures. a PFOA-treated glands have statistically significant reduced developmental
scores compared to controls in early life, as indicated by *. b Glands at 18 months. Large
arrow indicates area of increased stromal density in whole mounts (left) and H&E-stained
tissue (right); small arrow indicates area of ductal hyperplasia in H&E-stained tissue.
(Modified from Ref [33], with permission)
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Table 1
Possible mechanisms of endocrine disruption
• Affect synthesis of hormones
• Block/bind hormone receptors on target tissues
• Alter amount or activity of hormone receptors on target tissues
• Change signaling cascades by altering one or more steps in path
• Alter hormone metabolism
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Table 2
Summary of other EDC-induced reproductive effects
EDC Female reproductive Puberty: vaginal
opening (VO)
Hormones Male reproductive
BPA ↓Vaginal weights [52] @ High doses
accelerates VO [157]
♀- @ Low doses ↑
estradiol [51]
↑Organ weights [51]
@ Low oral doses no
effect [57]
♀♂- ↓ LH [52] ↓Sperm production /
motility [51]
♂-↓ Testosterone [52] ↓ Epididymal, seminal
vesicle weights; ↑
prostate [52]
TCDD ↓Weight [68] Delays VO; irregular
cycles [65]
♀- ↓ Estradiol [64] ↑ Androgen organs [69]
No Effect [66] ↓ Sperm production [69]
Vinclozolin ↑ Urethra/masculinization [25] Irregular cycles [51] ♀-↓ Estradiol; ↑
luteinizing hormone
[51]
↓Sperm # and motility;
hypospadia [24, 25, 51]











Delays VO [108, 110,
111]








PFOA ↑Uterine weight [123, 125] Delays VO [122, 123] ♀- ↑ Progesterone [136] Leydig Cell adenomas
[126]




Phytoestrogen: Genistein ↑ Uterine-ovarian weights [68] Accelerates VO;
irregular cycles [150,
157]
NC ↓ Anogenital distance;
↑adrenal, pituitary,
testicular weights [150]
↓ Anogenital distance; [150]
Mycoestrogens ↑Ovarian dysfunction [157, 162] Accelerates VO;
irregular cycles [157,
162]
♀- ↓ Estradiol; altered
progesterone [162]
↓ Seminal vesicles and
testicular weight [162]
↑Uterine weights [162]
NC Not Covered; VO Vaginal Opening; LH luteinizing hormone; ↑=increased; ↓=decreased. In Pituitary Ovarian/Testicular Hormone column,
♀=Female effects, ♂=Male effects
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Table 3
Proposed influence of some EDCs on breast cancer risk, demonstrating the importance of exposure timing
EDC Stage During Which Exposure Occurs
In utero Pubertal Adult
BPA ↑ Risk (pumps; not high dose) [47, 53] ↑ Risk [57] ↑ Risk [52, 57]
↑ Risk (oral) [57]; shifted time of susceptibility to
DMBA [55, 58]
TCDD ↑ Risk [65, 66] ↓ Risk [66] ↑ Risk [71]
Vinclozolin Unclear; proposed ↑ risk [100] NC ↑ Risk [99]
Phthalates: Proposed ↑ risk [112] at high doses ↓ risk [111] NC NC
♂-Proposed ↑ risk [106]
PFOA Unclear; proposed low dose ↑ risk [35, 36, 124, 132,
133]
Unclear; proposed ↑ risk
[123, 135, 136]
Unclear; Proposed ↑ risk @
pregnancy [36, 133]
Phytoestrogen: Genistein ↑ Risk [100, 144, 150, 164] ↓ Risk [146, 147, 163] Proposed ↑ risk [66]
♂-Proposed ↑ risk [150, 152] No effect [147]
♂-No effect [146]
Mycoestrogens No Effect [164] ↓ Risk [163] Unclear
NC Not Covered; ↑=increased; ↓=decreased ♂=Male effects; Unless specified all effects are for female breast cancer risk
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